List view / Grid view
A multi-million investment is set to enhance UK medicines manufacturing in three key areas: intracellular drug delivery, digitalisation and automation and nucleic acid medicines.
Discover what is driving the oligonucleotide therapeutics sector as scientists navigate challenges such as financing and success-to-market.
A report reviewing the state of sterile oligonucleotide drug processing has recommended ways to aid development of terminal sterilisation processes.
A partnership between Novartis and NHS England includes a proposal to investigate processes that can increase the scale and efficacy of oligonucleotide manufacture.